Key Takeaway: Sofis has appointed Rafael Fraga as its new CEO, succeeding founder Reynaldo Mendes, who will remain involved in the company. This leadership change follows Arcadea Group's acquisition of a majority stake in Sofis earlier in 2026. Fraga brings significant experience in the software industry, which is anticipated to enhance the company's growth.
Price reaction · baseline $2.24 (2026-08-25 close) · hit pre-market · clean, no other RFL news in the window
day 0 close · peak
+2.2%
Market Sentiment Analysis
POSITIVE FACTORS
Appointment of an experienced CEO to lead the company.
Fraga's background in software is expected to benefit Sofis.
Arcadea Group's acquisition indicates confidence in Sofis' future.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+68%
120-day peak, hindsight
Typical move
11.7%
average across 3 past catalysts
Cash runway
~8 mo
Medium dilution risk
Full Press Release Details
TORONTO & RIO DE JANEIRO--(BUSINESS WIRE)--Sofis, a Brazilian healthcare software provider specializing in hemotherapy and cell therapy solutions, announced the appointment of Rafael Fraga as incoming Chief Executive Officer. Arcadea Group acquired a majority stake in Sofis earlier in 2026. Fraga joins founder Reynaldo Mendes, who will stay on in a leadership role with the business and transfer full responsibilities to Fraga over the coming months. Fraga is an experienced software executive who
Frequently Asked Questions
Who is the new CEO of Sofis?
Rafael Fraga has been appointed as the new CEO of Sofis.
What company acquired a majority stake in Sofis?
Arcadea Group acquired a majority stake in Sofis earlier in 2026.
Who will remain in a leadership role at Sofis?
Founder Reynaldo Mendes will stay on in a leadership role.
What is Sofis specialized in?
Sofis specializes in hemotherapy and cell therapy solutions.
Biotech snapshot
Cash runway
$30M liquidity · $2M/mo burn
~8 mo
Medium dilution risk
Catalyst track record
+68%
best trade around RFL's most recent catalyst
Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for RFL.